The U.S. Food and Drug Administration approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC.
Xalkori is an oral medication that blocks the activity of the ROS-1 protein in tumors that have ROS-1 gene alterations. This effect on ROS-1 may prevent NSCLC from growing and spreading.
Lung cancer is the leading cause of cancer-related deaths in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. ROS-1 gene alterations, thought to lead to abnormal cells, have been identified in various cancers, including NSCLC. ROS-1 gene alterations are present in approximately 1 percent of patients with NSCLC.
Xalkori Side effectsThe most common side effects of Xalkori are
- Vision disorders
- Nausea, diarrhea
- Vomiting, swelling (edema)
- liver problems (elevated transaminases)
- Fatigue, decreased appetite
- Upper respiratory infection
- Dizziness and numbness
- Tingling in the hands or feet (neuropathy).
- Fatal inflammation of the lungs
- Abnormal heartbeats and partial
- Complete loss of vision in one or both eyes
Xalkori Cost and DosageXalkori has 200mg potency and 250mg potency. One pack of Xalkori contains 60 capsules. Cost of 200mg Xalkori pack is £51,027 and 250mg is £51,600 approximately. This price may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.
Dosing interruption and/or dose reduction to 200 mg PO q12hr may be required based on safety and tolerability; decrease to 250 mg PO qDay if further reduction is needed.